Romidepsin is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Romidepsin becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Information about SaveRxCanada.to
List of countries where we can ship Romidepsin:
Latest news releases on Romidepsin:
Romidepsin, also known as Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs). Romidepsin is a natural product obtained from the bacterium Chromobacterium violaceum, and works by blocking enzymes known as histone deacetylases, thus inducing apoptosis.
Romidepsin is used to treat T-cell lymphoma affecting the skin (cutaneous T-cell lymphoma, or peripheral T-cell lymphoma). Romidepsin is given after at least one other cancer treatment did not work or has stopped working. Romidepsin may also be used for purposes not listed in this medication guide.
Romidepsin is approved to treat: Cutaneous T-cell lymphoma in patients who have already been treated with at least one other type of systemic therapy. Peripheral T-cell lymphoma in patients who have already been treated with at least one other type of therapy. Romidepsin is also being studied in the treatment of other types of cancer.
ISTODAX safely and effectively. See full prescribing information for ISTODAX. ISTODAX® (romidepsin) for injection, for intravenous use Initial U.S. Approval: 2009 -----RECENT MAJOR CHANGES----- Dosage and Administration (2.3) 11/2018
Romidepsin is a prodrug, where it becomes active once taken up into the cell. The active metabolite has a free thiol group, which interacts with zinc ions in the active site of class 1 and 2 HDAC enzymes, resulting in inhibition of its enzymatic activity. Certain tumors have over expressed HDACs and downregulated/mutated histone acetyltransferases.
Romidepsin was approved for cutaneous T-cell lymphoma after one line of therapy in 2009. In a case report of romidepsin, responses were noted in four patients with T-cell lymphomas (three cutaneous and 1 peripheral) after treatment with romidepsin (12.7 or 17.8 mg/m 2 weekly on days 1 and 5 of a three week cycle) .
Patients with cancer who take romidepsin may be at a greater risk of getting a severe health problem called tumor lysis syndrome (TLS).This may lead to death. Call your doctor right away if you have a fast or abnormal heartbeat; any passing out; trouble passing urine; muscle weakness or cramps; upset stomach, throwing up, diarrhea, or not able to eat; or feel sluggish.
ISTODAX should be handled in a manner consistent with recommended safe procedures for handling cytotoxic drugs. ISTODAX must be reconstituted with the supplied diluent and further diluted with 0.9% Sodium Chloride Injection, USP before intravenous infusion. • Each 10 mg single-use vial of ISTODAX (romidepsin) must be
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.
Romidepsin (FK228, depsipeptide)is a potent histone deacetylase 1 and 2 (HDAC1 and HDAC2) inhibitor with IC50 of 36 nM and 47 nM.Find all the information about Romidepsin (FK228) for cell signaling research.